Detecting Mutations Treatment in Plasma
While tissue samples are the standard for cancer molecular profiling, tissue can often be challenging to obtain. Surgical biopsy may be risky or impossible, the biopsy procedure may have resulted in insufficient or exhausted tissue, or the sample acquired resulted in poor quality DNA. Whatever the reason, plasma assays can provide a less invasive alternative or complement to tissue assays. Plasma assays also provide the added potential for economical and minimally invasive serial sampling. Follow It is an amplicon-based focused liquid biopsy panel that analyzes cell-free circulating tumor DNA (ctDNA) in plasma isolated from peripheral blood. The assay is designed to detect SNVs and CNVs commonly associated with multiple solid tumor types,as well as MSI-status.
Details
Sensitive and Reliable Results
Concentrations of ctDNA vary among tumor types and among individuals. This variability in ctDNA concentration creates the need for a highly sensitive technology to detect genomic mutations at lower concentrations. The Follow It assay detects mutations down to 0.1% variant allele frequency*.
Follow It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 38 known cancer-associated genes simultaneously.
Follow It targets genes for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.
Technical Specifications
- Genes : 3
- Hotspots : 337
- Exons : 26
- Turnaround Time : 3-5 days
- Mutation types : SNVs, deletions and insertions (up to 24bp) CNVs
- Sample Type : Blood
- Sample Requirement : 2 x 10 mL of blood in Streck tubes
Customer reviews
No reviews were found for Detecting Mutations Treatment in Plasma. Be the first to review!